Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Syndax Pharmaceuticals Inc Director's Dealing 2021

Apr 28, 2021

31977_dirs_2021-04-28_23491817-ab5d-4f9f-872c-609be227cba6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Syndax Pharmaceuticals Inc (SNDX)
CIK: 0001395937
Period of Report: 2021-04-26

Reporting Person: Meyers Michael L. (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-04-26 Common Stock P 500.00 $15.46 Acquired 15666.00 Direct